Horizon Pharma, Inc. – Trademark Portfolio

Entity Type: 03

Horizon Pharma, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include RAYOS and HORIZON PHARMA. The owner is based in Lake Forest, IL.

150 S.Saunders Road

Lake Forest, IL 60045

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Horizon Pharma, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Horizon Pharma, Inc. have?

Horizon Pharma, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 2 cancelled.

What trademark classes does Horizon Pharma, Inc. file in?

Horizon Pharma, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Horizon Pharma, Inc.'s most well-known trademarks?

Horizon Pharma, Inc.'s registered trademark portfolio includes well-known marks such as RAYOS and HORIZON PHARMA. These are among 3 currently registered trademarks in the portfolio.

What is Horizon Pharma, Inc.'s trademark registration success rate?

Horizon Pharma, Inc. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.